和譽(02256)抑制劑獲美國FDA批准實體瘤I期臨床試驗

《經濟通通訊社8日專訊》和譽(02256)附屬和譽醫藥宣布,其自主研發的抗耐藥突
變小分子成纖維細胞生長因子受體4(「FGFR4」)抑制劑ABSK012,獲美國食品藥
品監督管理局(「FDA」)批准可開展其單藥在晚期實體瘤患者中的首次人體(FIH)I期
臨床試驗。(mh)

Read More 

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *

Generated by Feedzy